Advances in PTFE Artificial Vascular Grafts for Enhanced Hemocompatibility

Cardiovascular disease remains one of the leading causes of mortality worldwide, creating a persistent demand for reliable artificial vascular grafts capable of replacing damaged or occluded human blood vessels. Among all synthetic vascular materials, polytetrafluoroethylene (PTFE) has emerged as the gold standard for clinical vascular prosthetics due to its exceptional chemical inertness, structural stability, and adaptable surface characteristics. In recent years, extensive material science and clinical research have focused specifically on improving the hemocompatibility of PTFE artificial vascular grafts, aiming to reduce thrombosis, platelet adhesion, inflammatory response, and intimal hyperplasia, which are the primary causes of graft failure in long-term implantation. Modern advanced PTFE vascular prosthetics built on high-purity PTFE SHEET raw materials have significantly upgraded overall biocompatibility, making them safer and more effective for complex vascular reconstruction surgeries.

Hemocompatibility is the core performance indicator that determines the in-vivo service life and clinical success rate of artificial vascular grafts. Traditional synthetic vascular materials often trigger adverse blood-material interactions, including platelet activation, fibrin deposition, and leukocyte adhesion, which gradually lead to thrombus formation and vascular stenosis. Pure PTFE inherently possesses better hemocompatibility than polyethylene terephthalate (PET), polyurethane (PU), and other polymer materials because of its ultra-low surface energy and non-adhesive molecular structure. However, untreated expanded PTFE grafts still exhibit insufficient endothelialization capacity, limiting their long-term patency especially in small-diameter vascular transplantation. Current research advances mainly focus on physical structure optimization, surface biological modification, and composite material blending to further enhance the hemocompatibility of PTFE vascular grafts.

Structural optimization technology represents the most mature advancement in improving PTFE vascular hemocompatibility. Advanced stretching and sintering processes precisely control the micro-porous structure of PTFE grafts, forming uniform micron-level pore distribution that simulates the microstructure of natural blood vessel walls. This optimized porous structure not only maintains excellent mechanical compliance and permeability but also provides suitable adhesion sites for endothelial progenitor cells, accelerating the formation of complete endothelial lining on the graft surface. A complete endothelial layer can effectively isolate foreign materials from blood components, inhibit platelet aggregation, and significantly reduce the risk of thrombosis. Precision-processed PTFE TUBE vascular blanks ensure consistent micro-pore uniformity across the entire graft length, avoiding local structural defects that easily cause blood turbulence and thrombus accumulation.

Biological surface modification has become a key technical breakthrough for high-hemocompatibility PTFE vascular grafts. Researchers have developed multiple modification strategies including heparin immobilization, collagen coating, peptide grafting, and endothelial cell capture technology. Heparin-bound PTFE grafts can continuously release anticoagulant components, effectively inhibiting the activation of coagulation factors in blood and greatly reducing acute thrombosis after implantation. Bioactive peptide modification can specifically capture circulating endothelial progenitor cells in the blood, achieving rapid in-situ endothelialization and forming a stable anti-thrombotic biological interface. Different from simple physical coating, covalent grafting modification ensures the long-term stability of bioactive layers, avoiding coating shedding and failure during long-term blood flushing and vascular stretching.

In addition to anti-thrombotic performance, modern advanced PTFE vascular grafts also optimize anti-inflammatory and anti-hyperplasia hemocompatibility. Natural vascular tissue can self-regulate inflammatory responses, while synthetic grafts often cause chronic foreign body inflammation, leading to intimal hyperplasia and vascular restenosis. Modified PTFE materials can effectively reduce macrophage adhesion and inflammatory cytokine release, alleviate chronic inflammatory stimulation after implantation, and inhibit excessive proliferation of vascular smooth muscle cells. This comprehensive hemocompatibility optimization greatly improves the long-term patency rate of PTFE vascular grafts, especially in high-risk patients with hyperlipidemia, hyperglycemia, and hypercoagulable state.

Clinical application data fully verifies the effectiveness of advanced hemocompatibility improvement technologies. The latest modified PTFE artificial vascular grafts show a significantly lower thrombosis rate and restenosis rate than traditional unmodified grafts in peripheral vascular bypass, hemodialysis access, and cardiovascular reconstruction surgeries. With the continuous progress of material modification and bionic structure design, PTFE artificial vascular grafts are gradually approaching the hemocompatibility level of autologous blood vessels, providing more reliable synthetic vascular replacement solutions for patients who lack suitable autologous vascular resources. In the future, intelligent responsive PTFE vascular grafts with real-time blood environment monitoring functions will further expand the clinical application value of PTFE vascular prosthetics.